Lipidor Ab (LIPI) - Cash Flow Conversion Efficiency

Latest as of June 2024: -0.130x

Based on the latest financial reports, Lipidor Ab (LIPI) has a cash flow conversion efficiency ratio of -0.130x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.11 Million ≈ $-227.39K USD) by net assets (Skr16.29 Million ≈ $1.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lipidor Ab - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Lipidor Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lipidor Ab debt and liabilities for a breakdown of total debt and financial obligations.

Lipidor Ab Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipidor Ab ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Catenon S.A
MC:COM
0.241x
Uniserve Communications Corp
V:USS
-0.065x
Ordinary Fully Paid Deferred Settlement
AU:88EDA
N/A
Pasithea Therapeutics Corp
NASDAQ:KTTA
-0.237x
Higher Way Electronic Co Ltd
TWO:3268
-0.040x
Tuju Setia Bhd
KLSE:5297
-0.334x
Smithson Investment Trust PLC
LSE:SSON
0.000x
Indivior PLC
LSE:INDV
-0.612x

Annual Cash Flow Conversion Efficiency for Lipidor Ab (2016–2024)

The table below shows the annual cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Lipidor Ab.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr7.72 Million
≈ $831.01K
Skr-16.08 Million
≈ $-1.73 Million
-2.082x -216.42%
2023-12-31 Skr-9.34 Million
≈ $-1.01 Million
Skr-16.70 Million
≈ $-1.80 Million
1.789x +109.84%
2022-12-31 Skr2.15 Million
≈ $230.94K
Skr-39.00 Million
≈ $-4.20 Million
-18.174x -5811.04%
2021-12-31 Skr43.52 Million
≈ $4.68 Million
Skr-13.38 Million
≈ $-1.44 Million
-0.307x -28.15%
2020-12-31 Skr63.66 Million
≈ $6.85 Million
Skr-15.27 Million
≈ $-1.64 Million
-0.240x +56.67%
2019-12-31 Skr26.83 Million
≈ $2.89 Million
Skr-14.85 Million
≈ $-1.60 Million
-0.554x -185.21%
2018-12-31 Skr14.45 Million
≈ $1.55 Million
Skr-2.81 Million
≈ $-301.86K
-0.194x +81.58%
2017-12-31 Skr3.48 Million
≈ $374.18K
Skr-3.66 Million
≈ $-394.30K
-1.054x +76.02%
2016-12-31 Skr833.68K
≈ $89.72K
Skr-3.66 Million
≈ $-394.30K
-4.395x --

About Lipidor Ab

ST:LIPI Sweden Drug Manufacturers - General
Market Cap
$18.82 Million
Skr174.88 Million SEK
Market Cap Rank
#25226 Global
#514 in Sweden
Share Price
Skr0.22
Change (1 day)
+0.00%
52-Week Range
Skr0.22 - Skr0.30
All Time High
Skr22.60
About

Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more